Superior long-term outcome of patients with early transformation of non-hodgkin lymphoma undergoing stem cell transplantation

Clinical Lymphoma, Myeloma and Leukemia

Volumn 12, Issue 6, 2012, Pages 406-411

  Reddy, Nishitha ^a   Oluwole, Olalekan ^a   Greer, John P ^a   Goodman, Stacey ^a   Engelhardt, Brian ^a   Jagasia, Madan H ^a   Savani, Bipin N ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Allogeneic stem cell transplant; Autologous stem cell transplant; Radioimmunotherapy; Transformed lymphoma

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CANCER SURVIVAL; EVENT FREE SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; RECURRENCE RISK; SURVIVAL RATE; TRANSFORMED NONHODGKIN LYMPHOMA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL TRANSFORMATION, NEOPLASTIC; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84869452342     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.07.003     Document Type: Article

References (26)

1. S.H. Bernstein, W.R. Burack The incidence, natural history, biology, and treatment of transformed lymphomas Hematology Am Soc Hematol Educ Program 2009 532 541
2. A.J. Al-Tourah, K.K. Gill, M. Chhanabhai Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma J Clin Oncol 26 2008 5165 5169
3. A. Clavert, S. Le Gouill, E. Brissot Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma Leuk Lymphoma 51 2010 1502 1508
4. N. Reddy, B.N. Savani Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach Biol Blood Marrow Transplant 17 2011 1265 1272
5. P. Hari, J. Carreras, M.J. Zhang Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning Biol Blood Marrow Transplant 14 2008 236 245
6. A.J. Al-Tourah, K.J. Savage, K.K. Gill Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma [Abstract] ASH Annual Meeting Abstracts 110 2007 790
7. A.J. Davies, A.Z. Rohatiner, S. Howell Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma J Clin Oncol 22 2004 1469 1479
8. M.S. Kaminski, A.D. Zelenetz, O.W. Press Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas J Clin Oncol 19 2001 3918 3928
9. J.M. Vose, R.L. Wahl, M. Saleh Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas J Clin Oncol 18 2000 1316 1323
10. H. Ghesquières, F. Berger, P. Felman Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis J Clin Oncol 24 2006 5234 5241
11. J. Cilley, J.N. Winter Radioimmunotherapy and autologous stem cell transplantation for the treatment of B-cell lymphomas Haematologica 91 2006 114 120
12. G. Barosi, A. Carella, M. Lazzarino Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation Haematologica 90 2005 1236 1257
13. M.B. Eide, G.F. Lauritzsen, G. Kvalheim High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas A Norwegian multi centre phase II study Br J Haematol 152 2011 600 610
14. I.F. Khouri, P. McLaughlin, R.M. Saliba Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab Blood 111 2008 5530 5536
15. A.J. Barrett, B.N. Savani Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents Leukemia 20 2006 1661 1672
16. E. Giné, S. Montoto, F. Bosch The follicular lymphoma international prognostic index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma Ann Oncol 17 2006 1539 1545
17. A.R. Rezvani, B. Storer, M. Maris Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma J Clin Oncol 26 2008 211 217
18. C.D. Williams, C.N. Harrison, T.A. Lister High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European bone marrow transplant registry J Clin Oncol 19 2001 727 735
19. R.T. Doocey, C.L. Toze, J.M. Connors Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma Br J Haematol 131 2005 223 230
20. J.W. Friedberg, A.S. Freedman High-dose therapy and stem cell transplantation in follicular lymphoma Ann Hematol 78 1999 203 211
21. A.K. Gopal, J.M. Pagel, J.G. Rajendran Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy Biol Blood Marrow Transplant 12 2006 697 702
22. I.F. Khouri, R.M. Saliba, C. Hosing Efficacy and safety of yttrium 90 (90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin's lymphoma (NHL) [Abstract] ASH Annual Meeting Abstracts 108 2006 315
23. T. Fietz, L. Uharek, C. Gentilini Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan Leuk Lymphoma 47 2006 59 63
24. J.W. Friedberg, P. Cohen, L. Chen Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study J Clin Oncol 26 2008 204 210
25. G. Visani, L. Malerba, P.M. Stefani BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients Blood 118 2011 3419 3425
26. M.S. Czuczman, J.M. Vose, T.E. Witzig The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin Br J Haematol 154 2011 477 481